Talis Biomedical Dirección
Dirección controles de criterios 1/4
Actualmente no disponemos de información suficiente sobre el CEO.
Información clave
Rob Kelley
Chief Executive Officer (CEO)
US$1.0m
Compensación total
| Porcentaje del salario del CEO | 54.1% |
| Permanencia del CEO | 2.8yrs |
| Participación del CEO | 0.04% |
| Permanencia media de la dirección | sin datos |
| Promedio de permanencia en la Junta Directiva | 2.8yrs |
Actualizaciones recientes de la dirección
Recent updates
We're A Little Worried About Talis Biomedical's (NASDAQ:TLIS) Cash Burn Rate
Aug 16
Talis Biomedical reports Q2 results
Aug 02Talis Biomedical Aims For Manufacturing Turnaround
Mar 17Talis Biomedical (NASDAQ:TLIS) Will Have To Spend Its Cash Wisely
Feb 08Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?
Nov 04Is Talis Biomedical (NASDAQ:TLIS) In A Good Position To Deliver On Growth Plans?
Jul 21News Flash: 4 Analysts Think Talis Biomedical Corporation (NASDAQ:TLIS) Earnings Are Under Threat
May 18Talis Biomedical Corporation (NASDAQ:TLIS) Just Reported First-Quarter Earnings: Have Analysts Changed Their Mind On The Stock?
May 14Análisis de compensación del CEO
| Fecha | Compensación total | Salario | Ingresos de la empresa |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$51m |
| Mar 31 2024 | n/a | n/a | -US$57m |
| Dec 31 2023 | US$1m | US$551k | -US$62m |
| Sep 30 2023 | n/a | n/a | -US$75m |
| Jun 30 2023 | n/a | n/a | -US$86m |
| Mar 31 2023 | n/a | n/a | -US$98m |
| Dec 31 2022 | US$2m | US$525k | -US$113m |
| Sep 30 2022 | n/a | n/a | -US$115m |
| Jun 30 2022 | n/a | n/a | -US$127m |
| Mar 31 2022 | n/a | n/a | -US$165m |
| Dec 31 2021 | US$2m | US$322k | -US$192m |
| Sep 30 2021 | n/a | n/a | -US$208m |
| Jun 30 2021 | n/a | n/a | -US$199m |
| Mar 31 2021 | n/a | n/a | -US$144m |
| Dec 31 2020 | US$2m | US$89k | -US$91m |
Compensación vs. Mercado: La compensación total de Rob($USD1.02M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD673.68K).
Compensación vs. Ingresos: La compensación de Rob ha sido consistente con los resultados de la empresa en el último año.
CEO
Rob Kelley (52 yo)
2.8yrs
Permanencia
US$1,019,331
Compensación
Mr. Robert Kelley, also known as Rob, MBA, has been Chief Executive Officer and Director of Talis Biomedical Corporation since December 8, 2021 and served as its Chief Commercial Officer since September 20...
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 2.8yrs | US$1.02m | 0.037% $ 1.4k | |
| Co-Founder & Director | 11.3yrs | US$89.22k | 0.97% $ 35.4k | |
| Lead Independent Director | 2.8yrs | US$117.10k | 0.76% $ 27.7k | |
| Independent Director | 8.6yrs | US$100.27k | 6.3% $ 229.8k | |
| Independent Director | 8.5yrs | US$99.27k | 0.23% $ 8.3k | |
| Independent Director | 1.3yrs | US$34.18k | 0.015% $ 547.9 | |
| Director | 1.5yrs | US$45.29k | 0% $ 0 |
2.8yrs
Permanencia media
57yo
Promedio de edad
Junta con experiencia: La junta directiva de TLIS no se considera experimentada (2.5 años de permanencia promedio), lo que sugiere una nueva junta directiva.